SCHEMBL15445783

SCHEMBL15445783

Cc1ccc2c(c1)c1cc(-c3ccc4c(c3)c3cc(C)ccc3n4-c3ccc(-n4c5ccccc5c5ccccc54)cc3)ccc1n2-c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
ATM Q13315 1/20 0.56
PTGER4 P35408 1/20 0.42
BCHE P06276 1/20 0.40
ACHE P22303 1/20 0.40
AKR1C4 P17516 1/20 0.40
AKR1C3 P42330 1/20 0.40
AKR1C2 P52895 1/20 0.40
AKR1C1 Q04828 1/20 0.40
TSPO P30536 1/20 0.39
HDAC4 P56524 1/20 0.39
ALDH1A1 P00352 5/20 0.39
RXFP1 Q9HBX9 2/20 0.39
FGFR1 P11362 1/20 0.39
GAA P10253 2/20 0.38
GFER P55789 1/20 0.38
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12674807 0.98 KDM4E (0.58) KDM4EL3MBTL1ATMPTGER4BCHE
SCHEMBL19101130 0.98 KDM4E (0.58) KDM4EL3MBTL1ATMPTGER4BCHE
SCHEMBL17691603 0.97 L3MBTL1 (0.53) KDM4EL3MBTL1ATMPTGER4BCHE
SCHEMBL26226193 0.97 KDM4E (0.53) KDM4EL3MBTL1ATMPTGER4BCHE
SCHEMBL16171496 0.97 KDM4E (0.53) KDM4EL3MBTL1ATMPTGER4BCHE
SCHEMBL25920142 0.95 KDM4E (0.50) KDM4EL3MBTL1ATMPTGER4BCHE
SCHEMBL17178965 0.95 KDM4E (0.50) KDM4EL3MBTL1ATMPTGER4BCHE
SCHEMBL13262472 0.95 KDM4E (0.48) KDM4EL3MBTL1ATMPTGER4BCHE
SCHEMBL15747048 0.95 KDM4E (0.58) KDM4EL3MBTL1ATMPTGER4AKR1C4
SCHEMBL26771005 0.95 KDM4E (0.58) KDM4EL3MBTL1ATMPTGER4AKR1C4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10707434-B2 Organic electroluminescence element, and material for organic electroluminescence element IDEMITSU KOSAN CO., LTD. (JP) 2020-07-07 US disclosed
US-20190019972-A1 ORGANIC ELECTROLUMINESCENCE ELEMENT, AND MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT IDEMITSU KOSAN CO., LTD. (JP) 2019-01-17 US disclosed
US-9564595-B2 Bis-carbazole derivative and organic electroluminescent element using same IDEMITSU KOSAN CO., LTD. (JP) 2017-02-07 US disclosed
US-9564595-B2 Bis-carbazole derivative and organic electroluminescent element using same IDEMITSU KOSAN CO., LTD. (JP) 2017-02-07 US disclosed
US-20140306207-A1 ORGANIC ELECTROLUMINESCENCE ELEMENT, AND MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT IDEMITSU KOSAN CO., LTD. (JP) 2014-10-16 US disclosed
EP-2690093-A1 BIS-CARBAZOLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME Idemitsu Kosan Co., Ltd. (JP) 2014-01-29 EP disclosed
US-20140008633-A1 BIS-CARBAZOLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME MITSUI CHEMICALS, INC (JP) 2014-01-09 US disclosed
US-20140008633-A1 BIS-CARBAZOLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME MITSUI CHEMICALS, INC (JP) 2014-01-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190019972-A1 ORGANIC ELECTROLUMINESCENCE ELEMENT, AND MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT LEF1, L1CAM, AGO2 KDM4E 3248/4885L3MBTL1 1678/4885ATM 2324/4885
US-10707434-B2 Organic electroluminescence element, and material for organic electroluminescence element LEF1, L1CAM, AGO2 KDM4E 3248/4885L3MBTL1 1678/4885ATM 2324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.